查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1840907

骨质疏鬆症药物市场（按药物类别、给药途径、剂型、分销管道、最终用户和患者性别划分）—2025-2032 年全球预测

Osteoporosis Drugs Market by Drug Class, Route Of Administration, Dosage Form, Distribution Channel, End User, Patient Gender - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，骨质疏鬆症治疗市场将成长至 137.6 亿美元，复合年增长率为 5.79%。

主要市场统计数据
基准年2024年 87.7亿美元
预计2025年 92.7亿美元
预测年份：2032年 137.6亿美元
复合年增长率（%） 5.79%

对不断发展的骨质疏鬆症治疗前景的简明而权威的介绍，整合了相关人员决策的临床、监管和商业性动态

受科学进步、患者人口结构变化和监管预期不断演变的驱动，骨质疏鬆症治疗领域正经历一段动态演变时期。本执行摘要总结了影响临床治疗途径和商业实践的关键进展，为临床医生、付款方、製造商和投资者提供了一个讨论框架。后续章节重点在于分子生物学创新、多样化的医疗服务模式以及医疗体系压力如何重塑治疗选择和相关人员的策略。

随着人口老化和骨骼健康意识的增强，临床需求与日益增加的差异化药物和给药方式交织在一起。同时，付款人审查和供应链漏洞促使製造商重新思考定价、合约和分销方式。这些因素需要领导者密切关注，以保持竞争力并确保患者获得药物。接下来的引言将为深入分析变革性转变、关税影响、细分市场细微差别、区域动态、竞争定位、实用建议以及本研究的方法论基础奠定基础。

全面检视快速改变骨质疏鬆症治疗方式和治疗市场动态的临床、技术和商业性变革

骨质疏鬆症的诊断、预防和治疗方式正在发生重大变革，这些变革正在影响临床、供应链和商业模式。科学创新正在拓展传统抗骨质疏鬆药物以外的治疗选择，包括旨在提高疗效和疗效持久性的新型作用机制和联合用药策略。同时，诊断准确性和骨折风险分层的进步正在推动更早的干预和更个人化的治疗流程，进而影响处方模式和纵向照护计画。

同时，以患者为中心的医疗理念与数位医疗的融合正在增强依从性策略和远端监控，并在整个医疗过程中创造新的接触点。製造商正在推出差异化的配方和剂型，以提高耐受性和便利性，而付款人则越来越关注基于价值的合约和实际结果。由于突发的供不应求和全球采购的复杂性，供应链优化和韧性正成为优先事项。总的来说，这些转变要求临床、监管和商业团队齐心协力，抓住不断变化的情况带来的机会。

深入评估近期美国关税如何改变整个骨质疏鬆症治疗生态系统的采购、製造和分销策略

美国近期的政策发展和贸易行动为药品采购、筹资策略和生产冗余，以缓解关税带来的成本压力和潜在延误。进口关税可能会改变原料药和成品药的投入成本，促使就供应协议和价格调整进行谈判，以在不损害患者负担能力的情况下保持商业性可行性。

医疗保健提供者和付款人也在做出调整，优先考虑国内供应可靠性，探索替代采购途径，并增加关键注射剂和其他剂型的库存缓衝。由于相关人员需要在供应安全与成本控制之间取得平衡，这些应对措施可能会导致通路利用率和处方行为的暂时变化。此外，监管途径和海关程序在商业化计划中变得越来越重要，申办方将关税风险评估纳入打入市场策略和生命週期管理。最终，关税变化的累积效应正在加速采购、合约签订和分销实践的策略调整，凸显了积极主动的供应链管治和相关人员协作参与的必要性。

将治疗层级、给药方式、剂量概况、管道、最终用户偏好和患者人口统计细微差别与商业策略联繫起来的细粒度细分洞察

細項分析揭示了不同治疗层级、给药途径、剂型、分销管道、最终用户环境和患者群体之间存在不同的需求模式和营运重点，因此需要製定量身定制的商业化方案。在药物类别中，市场考虑因素各不相同：双磷酸盐类药物注重长期依从性和成本效益；地Denosumab等单株抗体注重标靶机制和给药间隔；激素替代疗法与更广泛的内分泌管理相交叉；副甲状腺素类似物针对合成代谢反应；选择性雌激素受体调节平衡骨骼和全身效应。这些类别层面的差异会影响临床定位和讯息。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • 硬化蛋白抑制剂在降低老年患者骨折风险的新作用
  • 引入数位健康监测工具来追踪患者对骨质疏鬆症药物的依从性
  • Teriparatide biosimilar对现有骨质疏鬆症药物品牌定价策略的影响
  • 心血管安全性数据更新后的 Romosozumab 临床结果和市场渗透率
  • 将遗传风险评估纳入个人化骨质疏鬆症治疗的决策流程

第六章：2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

第 8 章：骨质疏鬆症药物市场（依药物类别）

  • 双磷酸盐
  • Denosumab
  • 荷尔蒙补充疗法
  • 副甲状腺素类似物
  • 选择性雌激素受体调节

9. 骨质疏鬆症药物市场（依给药途径）

  • 注射
  • 口服

第 10 章骨质疏鬆症治疗药物市场（以剂型）

  • 胶囊
  • 注射
  • 解决方案
  • 药片

第 11 章骨质疏鬆症药物市场（依分销管道）

  • 医院药房
  • 网路药局
  • 零售药局

第 12 章骨质疏鬆症药物市场（依最终使用者）

  • 诊所
  • 家庭医疗保健
  • 医院

第 13 章：骨质疏鬆症药物市场（依病患性别）

  • 女士
  • 男性

第十四章骨质疏鬆症药物市场（按地区）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章骨质疏鬆症药物市场（依类别）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章骨质疏鬆症药物市场（依国家）

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章竞争格局

  • 2024年市占率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • Amgen Inc.
    • Eli Lilly and Company
    • Merck & Co., Inc.
    • Novartis AG
    • GlaxoSmithKline plc
    • Pfizer Inc.
    • F. Hoffmann-La Roche Ltd
    • UCB SA
    • AbbVie Inc.
    • Teva Pharmaceutical Industries Ltd
Product Code: MRR-AD36CD8980EF

The Osteoporosis Drugs Market is projected to grow by USD 13.76 billion at a CAGR of 5.79% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 8.77 billion
Estimated Year [2025] USD 9.27 billion
Forecast Year [2032] USD 13.76 billion
CAGR (%) 5.79%

A concise authoritative introduction to the evolving osteoporosis treatment environment integrating clinical, regulatory, and commercial dynamics shaping stakeholder decisions

The osteoporosis therapeutic area is undergoing a period of dynamic evolution driven by scientific advances, changing patient demographics, and shifting regulatory expectations. This executive summary synthesizes the critical developments affecting clinical care pathways and commercial practices, framing the discussion for clinicians, payers, manufacturers, and investors. In the following sections, the narrative highlights how molecular innovation, delivery modality diversification, and health-system pressures are collectively reshaping treatment choices and stakeholder strategies.

As the population ages and awareness of bone health increases, clinical demand intersects with a growing pipeline of differentiated agents and delivery forms. Meanwhile, payer scrutiny and supply chain vulnerabilities are prompting manufacturers to rethink pricing, contracting, and distribution approaches. Taken together, these forces warrant close attention from leaders seeking to maintain competitiveness and ensure patient access. The introduction that follows sets the scene for deeper analysis of transformative shifts, tariff effects, segmentation nuances, regional dynamics, competitive positioning, practical recommendations, and methodological foundations supporting the study.

Comprehensive exploration of the seismic clinical, technological, and commercial shifts rapidly transforming osteoporosis care delivery and therapeutic market dynamics

Major transformative shifts are redefining how osteoporosis is diagnosed, prevented, and treated, with implications across clinical practice, supply chains, and commercial models. Scientific innovation has expanded therapeutic options beyond traditional antiresorptives to include novel mechanisms of action and combination strategies that aim to improve efficacy and durability of response. Concurrently, advances in diagnostic precision and fracture risk stratification are leading to earlier intervention and more individualized treatment algorithms, which in turn influence prescribing patterns and long-term care planning.

At the same time, patient-centered care philosophies and digital health integrations are elevating adherence strategies and remote monitoring, creating new touchpoints for engagement across continuum-of-care settings. Manufacturers are responding with differentiated formulations and administration formats to improve tolerability and convenience, while payers are increasingly focused on value-based contracting and real-world outcomes. Supply chain optimization and resilience are emerging as a priority, driven by episodic shortages and global sourcing complexities, prompting a re-evaluation of sourcing, manufacturing footprints, and contingency planning. Altogether, these shifts demand coordinated action across clinical, regulatory, and commercial teams to capture the opportunity presented by the changing landscape.

In-depth assessment of how recent United States tariff measures are reshaping sourcing, manufacturing, and distribution strategies across the osteoporosis therapeutics ecosystem

Recent policy developments and trade measures in the United States have introduced new considerations for pharmaceutical sourcing, pricing, and distribution that ripple through the osteoporosis therapeutic space. Manufacturers that rely on global supply chains have had to reassess procurement strategies and manufacturing redundancy to mitigate tariff-driven cost pressures and potential delays. Import tariffs can alter input costs for active pharmaceutical ingredients and finished dosage forms, prompting negotiations on supply agreements and price adjustments to preserve commercial viability without compromising patient affordability.

Healthcare providers and payers are also adapting by emphasizing domestic supply reliability, exploring alternative sourcing pathways, and increasing inventory buffering for critical injectables and other dosage forms. These responses can lead to temporary shifts in channel utilization and prescribing behavior as stakeholders balance supply certainty with cost containment. Additionally, regulatory pathways and customs procedures have become more salient in commercialization planning, with sponsors integrating tariff risk assessments into market entry strategies and lifecycle management. Ultimately, the cumulative effect of tariff changes is to accelerate strategic realignments across sourcing, contracting, and distribution practices, underscoring the need for proactive supply chain governance and collaborative stakeholder engagement.

Granular segmentation insights connecting therapeutic classes, administration modalities, dosage constructs, channels, end-user settings, and patient demographic nuances to commercial strategy

Segmentation analysis reveals differentiated demand patterns and operational priorities across therapeutic classes, administration routes, dosage formats, distribution channels, end-user settings, and patient demographics, each of which requires tailored commercialization approaches. Based on Drug Class, market considerations vary between Bisphosphonate therapies that emphasize long-term adherence and cost-effectiveness, monoclonal antibody treatments such as Denosumab that focus on targeted mechanisms and administration cadence, Hormone Replacement Therapy offerings that intersect with broader endocrine management, Parathyroid Hormone Analog agents that target anabolic responses, and Selective Estrogen Receptor Modulator options that balance skeletal benefit with systemic effects. These class-level distinctions influence clinical positioning and messaging.

Based on Route Of Administration, injectable products carry different storage, administration, and reimbursement implications compared with oral therapies, necessitating distinct supply chain and patient support models. Based on Dosage Form, the characteristics of capsule, injection, solution, and tablet formats affect patient adherence, manufacturing complexity, and distribution logistics. Based on Distribution Channel, the roles of hospital pharmacies, online pharmacies, and retail pharmacies shape access points, fulfillment strategies, and channel economics. Based on End User, the needs and procurement behaviors of clinics, home healthcare providers, and hospitals differ significantly, shaping packaging, training, and support services. Based on Patient Gender, clinical presentation, risk profiling, and therapeutic preferences may vary between female and male patients, informing engagement, trial design, and real-world evidence generation. Combined, these segmentation lenses guide prioritization of product development, market access pathways, and commercial execution to align with stakeholder expectations.

Strategic regional analysis of divergent healthcare systems, reimbursement landscapes, and adoption drivers influencing osteoporosis therapy access across global regions

Regional dynamics demonstrate clear variations in clinical practice norms, regulatory frameworks, reimbursement mechanisms, and healthcare infrastructure that influence how osteoporosis therapies are adopted and utilized. In the Americas, a pronounced emphasis on value-based care, specialty pharmacy pathways, and payer negotiation shapes formulary access and distribution strategies. Providers in this region increasingly favor interventions that demonstrate measurable outcomes in fracture reduction and adherence support, driving demand for therapies that can be integrated into existing care coordination models.

In Europe, Middle East & Africa, heterogeneous regulatory regimes and reimbursement environments create a mosaic of access realities, with some markets characterized by centralized procurement and others by fragmented, local decision making. This complexity necessitates adaptive pricing strategies and robust evidence packages tailored to country-specific HTA and payer expectations. In Asia-Pacific, rapid demographic aging, expanding primary care networks, and growing attention to chronic disease management are elevating demand for both preventive and therapeutic approaches, while local manufacturing capacity and regulatory pathways influence time to market. Across regions, differences in healthcare delivery models, patient engagement channels, and supply chain infrastructure require region-specific commercialization playbooks to optimize uptake and patient outcomes.

Insightful analysis of competitive strategies, partnership models, and innovation pathways that distinguish leading organizations within the osteoporosis therapeutic arena

Competitive positioning among leading pharmaceutical and biotechnology entities reflects diverse approaches to pipeline investment, lifecycle management, and differentiation through formulation and delivery innovations. Some organizations concentrate on incremental enhancements to established mechanisms of action, seeking to optimize dosing intervals, mitigate adverse effects, and improve adherence through patient-centric devices and support programs. Others prioritize first-in-class or best-in-class candidates that address unmet needs in fracture prevention and bone anabolism, leveraging biomarker-driven development and targeted clinical programs to establish clear therapeutic differentiation.

Partnerships and strategic alliances are increasingly common, with companies collaborating across研发, manufacturing, and distribution to accelerate time to market and enhance supply stability. Licensing agreements and co-promotion arrangements allow firms to combine scientific strengths with commercial reach. In parallel, specialty and contract manufacturing organizations play a critical role in ensuring quality and scalability for both injectable biologics and small-molecule dosage forms. Across competitive landscapes, companies that integrate robust real-world evidence generation, patient support services, and payer engagement into commercialization plans are better positioned to achieve sustained clinical adoption and long-term utilization.

Actionable strategic recommendations for manufacturers and stakeholders to fortify supply chains, optimize payer engagement, and accelerate patient-centric adoption of osteoporosis therapies

Industry leaders should prioritize a coherent set of actions that translate strategic intent into measurable outcomes across clinical, commercial, and operational domains. First, invest in resilient supply chain architectures by diversifying suppliers, increasing transparency into upstream inputs, and implementing dual-sourcing or regional manufacturing where feasible to mitigate tariff and disruption risks. Second, align clinical development and real-world evidence programs with payer evidence requirements to facilitate favorable reimbursement conversations and to demonstrate value beyond clinical trial endpoints.

Third, differentiate through patient-centric delivery innovations and adherence-support services that reduce barriers to initiation and persistence, thereby improving long-term outcomes. Fourth, adopt flexible pricing and contracting models, including performance-based arrangements where appropriate, to address payer demands for value while preserving commercial sustainability. Fifth, develop regionally tailored market access strategies that reflect local regulatory, reimbursement, and clinical practice nuances, supported by targeted stakeholder engagement. Finally, cultivate strategic collaborations across the ecosystem-spanning academic centers, specialty pharmacies, and technology providers-to accelerate innovation and expand patient reach. Implementing these recommendations will require cross-functional alignment and disciplined execution to translate insights into competitive advantage.

Rigorous mixed-methods research approach combining stakeholder input, literature synthesis, and scenario analysis to produce reliable strategic insights for osteoporosis therapeutics

The research methodology underpinning this analysis combined multiple qualitative and quantitative evidence streams to ensure robust and actionable conclusions. Primary research included structured interviews and consultations with clinicians, payers, supply chain experts, and commercial leaders to capture firsthand perspectives on clinical practice, procurement challenges, and adoption drivers. Secondary research encompassed regulatory guidance, clinical literature, and public disclosures to contextualize product attributes, safety profiles, and approval pathways. Data triangulation across sources helped validate thematic insights and reduce single-source bias.

Analytical techniques included segmentation mapping, scenario analysis for tariff and supply chain contingencies, and comparative competitive benchmarking to understand differentiation opportunities. Careful attention was paid to the integrity of data sources and the transferability of insights across regions and therapeutic classes. Where appropriate, sensitivity testing of strategic options was conducted to assess robustness under alternative operational assumptions. Together, these methods produced a rigorous evidence base that informs the strategic conclusions and recommendations presented in this executive summary.

Concluding synthesis highlighting strategic imperatives to navigate clinical innovation, payer pressures, and supply chain complexity within the osteoporosis sector

In conclusion, the osteoporosis treatment environment is characterized by meaningful clinical innovation, evolving payer expectations, and heightened supply chain scrutiny, each of which shapes how therapies are developed, accessed, and utilized. Strategic responses that integrate resilient sourcing, differentiated patient-centric value propositions, and payer-aligned evidence generation will be central to achieving durable clinical adoption and commercial success. Regional heterogeneity and segmentation complexity further underscore the need for adaptive, localized strategies coupled with robust global coordination.

Leaders who proactively address tariff-related supply risks, invest in real-world outcomes measurement, and design services that support adherence will be better positioned to meet clinician and patient needs while satisfying payer demands. By executing against the recommended priorities and leveraging collaborative partnerships across the ecosystem, organizations can navigate current headwinds and capitalize on opportunities to improve bone health outcomes at scale.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Emerging role of sclerostin inhibitors in reducing fracture risk among elderly patients
  • 5.2. Adoption of digital health monitoring tools for tracking patient adherence to osteoporosis medications
  • 5.3. Impact of biosimilar teriparatide entry on pricing strategies of established osteoporosis brands
  • 5.4. Clinical outcomes and market uptake of romosozumab following cardiovascular safety data updates
  • 5.5. Integration of genetic risk assessment in personalized osteoporosis treatment decision making processes

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Osteoporosis Drugs Market, by Drug Class

  • 8.1. Bisphosphonate
  • 8.2. Denosumab
  • 8.3. Hormone Replacement Therapy
  • 8.4. Parathyroid Hormone Analog
  • 8.5. Selective Estrogen Receptor Modulator

9. Osteoporosis Drugs Market, by Route Of Administration

  • 9.1. Injectable
  • 9.2. Oral

10. Osteoporosis Drugs Market, by Dosage Form

  • 10.1. Capsule
  • 10.2. Injection
  • 10.3. Solution
  • 10.4. Tablet

11. Osteoporosis Drugs Market, by Distribution Channel

  • 11.1. Hospital Pharmacies
  • 11.2. Online Pharmacies
  • 11.3. Retail Pharmacies

12. Osteoporosis Drugs Market, by End User

  • 12.1. Clinics
  • 12.2. Home Healthcare
  • 12.3. Hospitals

13. Osteoporosis Drugs Market, by Patient Gender

  • 13.1. Female
  • 13.2. Male

14. Osteoporosis Drugs Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Osteoporosis Drugs Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Osteoporosis Drugs Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Amgen Inc.
    • 17.3.2. Eli Lilly and Company
    • 17.3.3. Merck & Co., Inc.
    • 17.3.4. Novartis AG
    • 17.3.5. GlaxoSmithKline plc
    • 17.3.6. Pfizer Inc.
    • 17.3.7. F. Hoffmann-La Roche Ltd
    • 17.3.8. UCB S.A.
    • 17.3.9. AbbVie Inc.
    • 17.3.10. Teva Pharmaceutical Industries Ltd

LIST OF FIGURES

  • FIGURE 1. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY PATIENT GENDER, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY PATIENT GENDER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS OSTEOPOROSIS DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA OSTEOPOROSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA OSTEOPOROSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA OSTEOPOROSIS DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE OSTEOPOROSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST OSTEOPOROSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA OSTEOPOROSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC OSTEOPOROSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN OSTEOPOROSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC OSTEOPOROSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION OSTEOPOROSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS OSTEOPOROSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 OSTEOPOROSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO OSTEOPOROSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. OSTEOPOROSIS DRUGS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. OSTEOPOROSIS DRUGS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. OSTEOPOROSIS DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY BISPHOSPHONATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY BISPHOSPHONATE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY BISPHOSPHONATE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY BISPHOSPHONATE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY BISPHOSPHONATE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY BISPHOSPHONATE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY DENOSUMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY DENOSUMAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY DENOSUMAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY DENOSUMAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY DENOSUMAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY DENOSUMAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY PARATHYROID HORMONE ANALOG, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY PARATHYROID HORMONE ANALOG, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY PARATHYROID HORMONE ANALOG, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY PARATHYROID HORMONE ANALOG, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY PARATHYROID HORMONE ANALOG, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY PARATHYROID HORMONE ANALOG, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY SELECTIVE ESTROGEN RECEPTOR MODULATOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY SELECTIVE ESTROGEN RECEPTOR MODULATOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY SELECTIVE ESTROGEN RECEPTOR MODULATOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY SELECTIVE ESTROGEN RECEPTOR MODULATOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY SELECTIVE ESTROGEN RECEPTOR MODULATOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY SELECTIVE ESTROGEN RECEPTOR MODULATOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY INJECTABLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY CAPSULE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY CAPSULE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY CAPSULE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY CAPSULE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY CAPSULE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY CAPSULE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY INJECTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY INJECTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY INJECTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY INJECTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY INJECTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY INJECTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY SOLUTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY SOLUTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY SOLUTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY SOLUTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY SOLUTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY SOLUTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY TABLET, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY TABLET, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY TABLET, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY TABLET, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY TABLET, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY PATIENT GENDER, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY PATIENT GENDER, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY FEMALE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY FEMALE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY FEMALE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY FEMALE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY FEMALE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY FEMALE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY MALE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY MALE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY MALE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY MALE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY MALE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY MALE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. AMERICAS OSTEOPOROSIS DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 134. AMERICAS OSTEOPOROSIS DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 135. AMERICAS OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 136. AMERICAS OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 137. AMERICAS OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 138. AMERICAS OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 139. AMERICAS OSTEOPOROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 140. AMERICAS OSTEOPOROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 141. AMERICAS OSTEOPOROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 142. AMERICAS OSTEOPOROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 143. AMERICAS OSTEOPOROSIS DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 144. AMERICAS OSTEOPOROSIS DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 145. AMERICAS OSTEOPOROSIS DRUGS MARKET SIZE, BY PATIENT GENDER, 2018-2024 (USD MILLION)
  • TABLE 146. AMERICAS OSTEOPOROSIS DRUGS MARKET SIZE, BY PATIENT GENDER, 2025-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA OSTEOPOROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. NORTH AMERICA OSTEOPOROSIS DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. NORTH AMERICA OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 150. NORTH AMERICA OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 152. NORTH AMERICA OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA OSTEOPOROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 154. NORTH AMERICA OSTEOPOROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA OSTEOPOROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 156. NORTH AMERICA OSTEOPOROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA OSTEOPOROSIS DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 158. NORTH AMERICA OSTEOPOROSIS DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA OSTEOPOROSIS DRUGS MARKET SIZE, BY PATIENT GENDER, 2018-2024 (USD MILLION)
  • TABLE 160. NORTH AMERICA OSTEOPOROSIS DRUGS MARKET SIZE, BY PATIENT GENDER, 2025-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA OSTEOPOROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. LATIN AMERICA OSTEOPOROSIS DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. LATIN AMERICA OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 164. LATIN AMERICA OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 165. LATIN AMERICA OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 166. LATIN AMERICA OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA OSTEOPOROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 168. LATIN AMERICA OSTEOPOROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 169. LATIN AMERICA OSTEOPOROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 170. LATIN AMERICA OSTEOPOROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 171. LATIN AMERICA OSTEOPOROSIS DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 172. LATIN AMERICA OSTEOPOROSIS DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA OSTEOPOROSIS DRUGS MARKET SIZE, BY PATIENT GENDER, 2018-2024 (USD MILLION)
  • TABLE 174. LATIN AMERICA OSTEOPOROSIS DRUGS MARKET SIZE, BY PATIENT GENDER, 2025-2032 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA OSTEOPOROSIS DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA OSTEOPOROSIS DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 178. EUROPE, MIDDLE EAST & AFRICA OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 180. EUROPE, MIDDLE EAST & AFRICA OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 181. EUROPE, MIDDLE EAST & AFRICA OSTEOPOROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 182. EUROPE, MIDDLE EAST & AFRICA OSTEOPOROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 183. EUROPE, MIDDLE EAST & AFRICA OSTEOPOROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 184. EUROPE, MIDDLE EAST & AFRICA OSTEOPOROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 185. EUROPE, MIDDLE EAST & AFRICA OSTEOPOROSIS DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 186. EUROPE, MIDDLE EAST & AFRICA OSTEOPOROSIS DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 187. EUROPE, MIDDLE EAST & AFRICA OSTEOPOROSIS DRUGS MARKET SIZE, BY PATIENT GENDER, 2018-2024 (USD MILLION)
  • TABLE 188. EUROPE, MIDDLE EAST & AFRICA OSTEOPOROSIS DRUGS MARKET SIZE, BY PATIENT GENDER, 2025-2032 (USD MILLION)
  • TABLE 189. EUROPE OSTEOPOROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. EUROPE OSTEOPOROSIS DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. EUROPE OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 192. EUROPE OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 193. EUROPE OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 194. EUROPE OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 195. EUROPE OSTEOPOROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 196. EUROPE OSTEOPOROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 197. EUROPE OSTEOPOROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 198. EUROPE OSTEOPOROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 199. EUROPE OSTEOPOROSIS DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 200. EUROPE OSTEOPOROSIS DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 201. EUROPE OSTEOPOROSIS DRUGS MARKET SIZE, BY PATIENT GENDER, 2018-2024 (USD MILLION)
  • TABLE 202. EUROPE OSTEOPOROSIS DRUGS MARKET SIZE, BY PATIENT GENDER, 2025-2032 (USD MILLION)
  • TABLE 203. MIDDLE EAST OSTEOPOROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. MIDDLE EAST OSTEOPOROSIS DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. MIDDLE EAST OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 206. MIDDLE EAST OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 207. MIDDLE EAST OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 208. MIDDLE EAST OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 209. MIDDLE EAST OSTEOPOROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 210. MIDDLE EAST OSTEOPOROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 211. MIDDLE EAST OSTEOPOROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 212. MIDDLE EAST OSTEOPOROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 213. MIDDLE EAST OSTEOPOROSIS DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 214. MIDDLE EAST OSTEOPOROSIS DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 215. MIDDLE EAST OSTEOPOROSIS DRUGS MARKET SIZE, BY PATIENT GENDER, 2018-2024 (USD MILLION)
  • TABLE 216. MIDDLE EAST OSTEOPOROSIS DRUGS MARKET SIZE, BY PATIENT GENDER, 2025-2032 (USD MILLION)
  • TABLE 217. AFRICA OSTEOPOROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. AFRICA OSTEOPOROSIS DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. AFRICA OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 220. AFRICA OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 221. AFRICA OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 222. AFRICA OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 223. AFRICA OSTEOPOROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 224. AFRICA OSTEOPOROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 225. AFRICA OSTEOPOROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 226. AFRICA OSTEOPOROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 227. AFRICA OSTEOPOROSIS DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 228. AFRICA OSTEOPOROSIS DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 229. AFRICA OSTEOPOROSIS DRUGS MARKET SIZE, BY PATIENT GENDER, 2018-2024 (USD MILLION)
  • TABLE 230. AFRICA OSTEOPOROSIS DRUGS MARKET SIZE, BY PATIENT GENDER, 2025-2032 (USD MILLION)
  • TABLE 231. ASIA-PACIFIC OSTEOPOROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 232. ASIA-PACIFIC OSTEOPOROSIS DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 233. ASIA-PACIFIC OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 234. ASIA-PACIFIC OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 235. ASIA-PACIFIC OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 236. ASIA-PACIFIC OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 237. ASIA-PACIFIC OSTEOPOROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 238. ASIA-PACIFIC OSTEOPOROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 239. ASIA-PACIFIC OSTEOPOROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 240. ASIA-PACIFIC OSTEOPOROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 241. ASIA-PACIFIC OSTEOPOROSIS DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 242. ASIA-PACIFIC OSTEOPOROSIS DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 243. ASIA-PACIFIC OSTEOPOROSIS DRUGS MARKET SIZE, BY PATIENT GENDER, 2018-2024 (USD MILLION)
  • TABLE 244. ASIA-PACIFIC OSTEOPOROSIS DRUGS MARKET SIZE, BY PATIENT GENDER, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 247. ASEAN OSTEOPOROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. ASEAN OSTEOPOROSIS DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. ASEAN OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 250. ASEAN OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 251. ASEAN OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 252. ASEAN OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 253. ASEAN OSTEOPOROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 254. ASEAN OSTEOPOROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 255. ASEAN OSTEOPOROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 256. ASEAN OSTEOPOROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 257. ASEAN OSTEOPOROSIS DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 258. ASEAN OSTEOPOROSIS DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 259. ASEAN OSTEOPOROSIS DRUGS MARKET SIZE, BY PATIENT GENDER, 2018-2024 (USD MILLION)
  • TABLE 260. ASEAN OSTEOPOROSIS DRUGS MARKET SIZE, BY PATIENT GENDER, 2025-2032 (USD MILLION)
  • TABLE 261. GCC OSTEOPOROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 262. GCC OSTEOPOROSIS DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 263. GCC OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 264. GCC OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 265. GCC OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 266. GCC OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 267. GCC OSTEOPOROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 268. GCC OSTEOPOROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 269. GCC OSTEOPOROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 270. GCC OSTEOPOROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 271. GCC OSTEOPOROSIS DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 272. GCC OSTEOPOROSIS DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 273. GCC OSTEOPOROSIS DRUGS MARKET SIZE, BY PATIENT GENDER, 2018-2024 (USD MILLION)
  • TABLE 274. GCC OSTEOPOROSIS DRUGS MARKET SIZE, BY PATIENT GENDER, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPEAN UNION OSTEOPOROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPEAN UNION OSTEOPOROSIS DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPEAN UNION OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPEAN UNION OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPEAN UNION OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPEAN UNION OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPEAN UNION OSTEOPOROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPEAN UNION OSTEOPOROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 283. EUROPEAN UNION OSTEOPOROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPEAN UNION OSTEOPOROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 285. EUROPEAN UNION OSTEOPOROSIS DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPEAN UNION OSTEOPOROSIS DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 287. EUROPEAN UNION OSTEOPOROSIS DRUGS MARKET SIZE, BY PATIENT GENDER, 2018-2024 (USD MILLION)
  • TABLE 288. EUROPEAN UNION OSTEOPOROSIS DRUGS MARKET SIZE, BY PATIENT GENDER, 2025-2032 (USD MILLION)
  • TABLE 289. BRICS OSTEOPOROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 290. BRICS OSTEOPOROSIS DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 291. BRICS OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 292. BRICS OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 293. BRICS OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 294. BRICS OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 295. BRICS OSTEOPOROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 296. BRICS OSTEOPOROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 297. BRICS OSTEOPOROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 298. BRICS OSTEOPOROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 299. BRICS OSTEOPOROSIS DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 300. BRICS OSTEOPOROSIS DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 301. BRICS OSTEOPOROSIS DRUGS MARKET SIZE, BY PATIENT GENDER, 2018-2024 (USD MILLION)
  • TABLE 302. BRICS OSTEOPOROSIS DRUGS MARKET SIZE, BY PATIENT GENDER, 2025-2032 (USD MILLION)
  • TABLE 303. G7 OSTEOPOROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 304. G7 OSTEOPOROSIS DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 305. G7 OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 306. G7 OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 307. G7 OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 308. G7 OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 309. G7 OSTEOPOROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 310. G7 OSTEOPOROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 311. G7 OSTEOPOROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 312. G7 OSTEOPOROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 313. G7 OSTEOPOROSIS DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 314. G7 OSTEOPOROSIS DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 315. G7 OSTEOPOROSIS DRUGS MARKET SIZE, BY PATIENT GENDER, 2018-2024 (USD MILLION)
  • TABLE 316. G7 OSTEOPOROSIS DRUGS MARKET SIZE, BY PATIENT GENDER, 2025-2032 (USD MILLION)
  • TABLE 317. NATO OSTEOPOROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 318. NATO OSTEOPOROSIS DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 319. NATO OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 320. NATO OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 321. NATO OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 322. NATO OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 323. NATO OSTEOPOROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 324. NATO OSTEOPOROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 325. NATO OSTEOPOROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 326. NATO OSTEOPOROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 327. NATO OSTEOPOROSIS DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 328. NATO OSTEOPOROSIS DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 329. NATO OSTEOPOROSIS DRUGS MARKET SIZE, BY PATIENT GENDER, 2018-2024 (USD MILLION)
  • TABLE 330. NATO OSTEOPOROSIS DRUGS MARKET SIZE, BY PATIENT GENDER, 2025-2032 (USD MILLION)
  • TABLE 331. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 332. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 333. UNITED STATES OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 334. UNITED STATES OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 335. UNITED STATES OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 336. UNITED STATES OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 337. UNITED STATES OSTEOPOROSIS DRUGS MARKET SIZE, BY D